Developing An Online Course On Chronic Myeloid Leukaemia For Postgraduate Medical Students ( Co-Researcher)

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO R-CHOP VERSUS R-CHOP IN PREVIOUSLY UNTREATED, HIGH-INTERMEDIATE AND HIGH-RISK PATIENTS WITH NEWLY-DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) ( Co-Researcher)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE CLINICAL OUTCOMES, ANTIVIRAL ACTIVITY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACOKINETICS/PHARMACODYNAMICS OF JNJ-53718678 IN ADULT AND ADOLESCENT HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION OF THE UPPER RESPIRATORY TRACT ( Co-Researcher)

A PHASE 2B, OPEN-LABEL, MULTICENTER, RANDOMIZED, CONTROLLED, 2-ARM STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA (PLATELET COUNT ( Co-Researcher)

A PHASE 3, RANDOMIZED STUDY TO COMPARE NEMTABRUTINIB VERSUS COMPARATOR (INVESTIGATOR S CHOICE OF IBRUTINIB OR ACALABRUTINIB) IN PARTICIPANTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BELLWAVE-011) ( Co-Researcher)

AN OPEN-LABEL, MULTICENTER, ROLL-OVER STUDY FOR PATIENTS WHO HAVE COMPLETED A PRIOR NOVARTIS-SPONSORED SABATOLIMAB (MBG453) STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT WITH SABATOLIMAB ( Co-Researcher)

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF GOLCADOMIDE PLUS R-CHOP CHEMOTHERAPY VS PLACEBO PLUS R-CHOP CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED HIGH-RISK LARGE B-CELL LYMPHOMA (GOLSEEK-1) ( Co-Researcher)

A PHASE IIIB, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF TOLERABILITY AND EFFICACY OF ORAL ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE ( Co-Researcher)

AN OPEN-LABEL, PHASE 2 TRIAL OF NANATINOSTAT IN COMBINATION WITH VALGANCICLOVIR IN PATIENTS WITH EPSTEIN-BARR VIRUS-POSITIVE (EBV+) RELAPSED/REFRACTORY LYMPHOMAS (NAVAL-1) ( Co-Researcher)

Developing A Masterclass In Chronic Myeloid Leukaemia ( Co-Researcher)

A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients ( Principal Investigator(PI))

AN OPEN-LABEL, DOSE-ESCALATION, DOSE-FINDING, AND PROOF-OF-CONCEPT TRIAL OF SP-420 IN SUBJECTS WITH TRANSFUSION-DEPENDENT - OR -THALASSEMIA OR LOW-RISK MYELODYSPLASTIC SYNDROMES ( Co-Researcher)

EFFICACY AND SAFETY OF M281 IN ADULTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH A LONG-TERM OPEN-LABEL EXTENSION ( Co-Researcher)

A MULTICENTER RETROSPECTIVE STUDY TO UNDERSTAND THE CLINICAL CHARACTERISTICS, TREATMENT PATHWAY AND RESOURCE UTILIZATION FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). ( Co-Researcher)

Randomized Phase 3 study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) versus Pomalidomide-Dexamethasone (PD) in relapse or refractory myeloma. An AMN study ( Co-Researcher)

Investigating the Impact of Genetic Polymorphisms on Renal Failure in Patients Receiving High-Dose Methotrexate Therapy: A Clinical Approach ( Co-Researcher)